HemOnc Today


The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents

Ramucirumab improves PFS in advanced urothelial carcinoma

‘Explosive growth’ of interventional oncology prompts formation of new society

OncoSec, Merck to collaborate on trial of ImmunoPulse IL-12, pembrolizumab in metastatic melanoma

Indo-American Cancer Association honors City of Hope researcher

Geneticist to lead Vanderbilt cancer center’s health disparities program

Durvalumab extends PFS in advanced NSCLC

Oncology leaders: Biden Cancer Initiative will continue moonshot’s momentum

Seattle Genetics halts trial of vadastuximab talirine for acute myeloid leukemia

University of Alabama at Birmingham appoints cancer center director

The Wistar Institute appoints associate professor

UT Health cancer center names director

Supreme Court ruling on biosimilars ‘a win’ for patients

Cover Story

FDA’s ‘breakneck pace’ accelerates drug access, but concerns persist about lack of complete data


Emperors, gladiators and handmaidens

Derek Raghavan, MD, PhD

FDA News

FDA grants breakthrough therapy designation to GMI-1271 for AML

FDA grants priority review to Keytruda for advanced gastric, gastroesophageal junction adenocarcinoma

FDA expands approval of Zykadia for ALK–positive metastatic NSCLC

FDA approves Rituxan Hycela subcutaneous injection for blood cancers

FDA rejects Coherus application for proposed biosimilar to Neulasta

FDA grants orphan drug designation to pIL-12 for unresectable melanoma

In the Journals Plus

Travel to academic centers improves pancreatic cancer survival

Prostate cancer therapies show different rates of adoption

Inhaled corticosteroids may benefit patients with sickle cell disease

Oral squamous cell carcinoma diagnosis affects sexual behavior

Alternative transfusion policy feasible for unknown blood types in emergency setting

Meeting News

Nivolumab shows promise for advanced cervical cancer

Momelotinib noninferior to ruxolitinib for spleen response in myelofibrosis

Responses appear durable after completion of pembrolizumab therapy for melanoma

Post-lumpectomy surgery rates for invasive breast cancer have declined

Pembrolizumab reduces need for second-line therapy in advanced NSCLC

Low testosterone levels prevalent among testicular cancer survivors

CAR T-cell immunotherapy prompts durable response for ALL

Childhood cancer survivors experience fewer severe health problems

CAR T-cell therapy shows promise for patients with myeloma


Should an independent regulatory body oversee the FDA drug approval process?


Meeting Update: Clinicians discuss findings, practice implications from ASCO Annual Meeting